| __timestamp | Arrowhead Pharmaceuticals, Inc. | BioMarin Pharmaceutical Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 23138050 | 461543000 |
| Thursday, January 1, 2015 | 57410147 | 634806000 |
| Friday, January 1, 2016 | 41454452 | 661905000 |
| Sunday, January 1, 2017 | 31690298 | 610753000 |
| Monday, January 1, 2018 | 52968505 | 696328000 |
| Tuesday, January 1, 2019 | 81048686 | 715007000 |
| Wednesday, January 1, 2020 | 128874979 | 628116000 |
| Friday, January 1, 2021 | 206342000 | 628793000 |
| Saturday, January 1, 2022 | 297307000 | 649606000 |
| Sunday, January 1, 2023 | 353188000 | 746773000 |
| Monday, January 1, 2024 | 505870000 | 747184000 |
Cracking the code
In the competitive world of biotechnology, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, BioMarin Pharmaceutical Inc. and Arrowhead Pharmaceuticals, Inc. have demonstrated contrasting strategies in their R&D investments.
BioMarin has consistently invested in R&D, with expenses peaking at approximately $747 million in 2023, marking a 62% increase from 2014. This steady growth underscores BioMarin's dedication to advancing its pipeline of therapies for rare diseases.
Conversely, Arrowhead Pharmaceuticals has shown a more volatile yet aggressive increase in R&D spending. From a modest $23 million in 2014, Arrowhead's R&D expenses surged to over $506 million by 2024, reflecting a remarkable 21-fold increase. This rapid expansion highlights Arrowhead's strategic focus on RNA interference therapeutics.
Both companies exemplify the dynamic nature of the biotech industry, where strategic R&D investments can drive innovation and growth.
Research and Development Expenses Breakdown: Takeda Pharmaceutical Company Limited vs BioMarin Pharmaceutical Inc.
Research and Development Expenses Breakdown: Bio-Techne Corporation vs BioMarin Pharmaceutical Inc.
Research and Development Expenses Breakdown: BioMarin Pharmaceutical Inc. vs Rhythm Pharmaceuticals, Inc.
R&D Insights: How BioMarin Pharmaceutical Inc. and Supernus Pharmaceuticals, Inc. Allocate Funds
BioMarin Pharmaceutical Inc. vs MannKind Corporation: Strategic Focus on R&D Spending
Who Prioritizes Innovation? R&D Spending Compared for Viking Therapeutics, Inc. and Arrowhead Pharmaceuticals, Inc.
Comparing Innovation Spending: Rhythm Pharmaceuticals, Inc. and Arrowhead Pharmaceuticals, Inc.
Analyzing R&D Budgets: HUTCHMED (China) Limited vs Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc. vs Ligand Pharmaceuticals Incorporated: Strategic Focus on R&D Spending
Research and Development: Comparing Key Metrics for Arrowhead Pharmaceuticals, Inc. and Amphastar Pharmaceuticals, Inc.
R&D Insights: How Arrowhead Pharmaceuticals, Inc. and Evotec SE Allocate Funds
Research and Development: Comparing Key Metrics for Arrowhead Pharmaceuticals, Inc. and BioCryst Pharmaceuticals, Inc.